GLSI Insider Transactions
| Transaction Date (SEC Report) |
Reporting Name | Relationship | Shrs. Owned | Type | Acq./Disp. | Shrs. Transacted | Price() | Amount() |
|---|---|---|---|---|---|---|---|---|
| 2024-04-01 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,350,777 | P-Purchase | A | 3,000 | 19.08 | 57,240.00 |
| 2024-03-22 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,347,777 | P-Purchase | A | 2,500 | 19.98 | 49,950.00 |
| 2024-03-20 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,345,277 | P-Purchase | A | 1,500 | 17.68 | 26,520.00 |
| 2024-03-05 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,343,777 | P-Purchase | A | 30,500 | 12.49 | 380,945.00 |
| 2024-03-04 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,340,277 | P-Purchase | A | 4,100 | 13.03 | 53,423.00 |
| 2024-02-16 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,336,177 | P-Purchase | A | 10,800 | 11.16 | 120,528.00 |
| 2024-02-15 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,325,377 | P-Purchase | A | 12,700 | 11.07 | 140,589.00 |
| 2023-11-10 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,312,677 | P-Purchase | A | 5,000 | 10.17 | 50,838.00 |
| 2023-11-03 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,307,677 | P-Purchase | A | 3,500 | 9.11 | 31,885.00 |
| 2023-10-27 | Thompson Jaye | officer: VP Clinical Reg Affairs | 260,348 | P-Purchase | A | 500 | 8.57 | 4,285.00 |
| 2023-10-26 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,304,177 | P-Purchase | A | 2,500 | 7.97 | 19,925.00 |
| 2023-10-25 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,301,677 | P-Purchase | A | 2,500 | 7.91 | 19,775.00 |
| 2023-10-10 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,299,177 | P-Purchase | A | 1,000 | 9.07 | 9,070.00 |
| 2023-10-04 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,298,177 | P-Purchase | A | 2,000 | 8.63 | 17,260.00 |
| 2023-09-26 | Thompson Jaye | officer: VP Clinical Reg Affairs | 259,848 | P-Purchase | A | 600 | 8.71 | 5,226.00 |
| 2023-09-19 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,296,177 | P-Purchase | A | 4,000 | 8.95 | 35,800.00 |
| 2023-09-11 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,292,177 | P-Purchase | A | 1,000 | 9.48 | 9,480.00 |
| 2023-08-22 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,291,177 | P-Purchase | A | 1,000 | 9.97 | 9,970.00 |
| 2023-08-04 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,290,177 | P-Purchase | A | 2,000 | 10.55 | 21,100.00 |
| 2023-07-21 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,288,177 | P-Purchase | A | 1,000 | 9.20 | 9,200.00 |
| 2023-07-13 | Thompson Jaye | officer: VP Clinical Reg Affairs | 259,248 | P-Purchase | A | 250 | 9.49 | 2,372.00 |
| 2023-05-17 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,287,177 | P-Purchase | A | 1,000 | 11.69 | 11,690.00 |
| 2023-04-28 | Thompson Jaye | officer: VP Clinical Reg Affairs | 258,998 | P-Purchase | A | 250 | 11.22 | 2,805.00 |
| 2023-04-19 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,286,177 | P-Purchase | A | 7,000 | 11.10 | 77,700.00 |
| 2023-04-18 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,279,177 | P-Purchase | A | 2,000 | 11.12 | 22,240.00 |
| 2023-04-11 | Thompson Jaye | officer: VP Clinical Reg Affairs | 258,745 | P-Purchase | A | 1,000 | 11.87 | 11,870.00 |
| 2023-04-11 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 5,271,177 | P-Purchase | A | 5,000 | 12.42 | 62,100.00 |
| 2023-03-15 | Thompson Jaye | officer: VP Clinical Reg Affairs | 257,745 | P-Purchase | A | 250 | 12.71 | 3,178.00 |
| 2023-03-10 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 2,737,486 | P-Purchase | A | 1,000 | 12.12 | 12,120.00 |
| 2023-02-24 | Thompson Jaye | officer: VP Clinical Reg Affairs | 257,495 | P-Purchase | A | 250 | 15.40 | 3,849.00 |
| 2023-02-17 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 2,736,486 | P-Purchase | A | 600 | 16.53 | 9,918.00 |
| 2023-02-10 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 2,735,886 | P-Purchase | A | 1,000 | 18.68 | 18,680.00 |
| 2023-02-03 | Thompson Jaye | officer: VP Clinical Reg Affairs | 257,245 | P-Purchase | A | 250 | 20.84 | 5,210.00 |
| 2023-01-27 | Patel Snehal | officer: CEO and CFO | 2,734,886 | P-Purchase | A | 2,000 | 19.35 | 38,700.00 |
| 2023-01-27 | Thompson Jaye | officer: VP Clinical Reg Affairs | 256,995 | P-Purchase | A | 250 | 19.20 | 4,800.00 |
| 2023-01-20 | Patel Snehal | officer: CEO and CFO | 2,732,886 | P-Purchase | A | 1,500 | 17.37 | 26,055.00 |
| 2023-01-13 | Thompson Jaye | officer: VP Clinical Reg Affairs | 256,745 | P-Purchase | A | 250 | 16.50 | 4,125.00 |
| 2023-01-06 | Patel Snehal | officer: CEO and CFO | 2,731,386 | P-Purchase | A | 1,500 | 15.18 | 22,770.00 |
| 2022-12-29 | Patel Snehal | officer: CEO and CFO | 2,729,886 | P-Purchase | A | 4,000 | 15.19 | 60,760.00 |
| 2022-12-16 | Patel Snehal | officer: CEO and CFO | 2,725,886 | P-Purchase | A | 1,000 | 13.01 | 13,010.00 |
| 2022-12-16 | Thompson Jaye | officer: VP Clinical Reg Affairs | 256,495 | P-Purchase | A | 250 | 12.94 | 3,235.00 |
| 2022-12-09 | Patel Snehal | officer: CEO and CFO | 2,724,886 | P-Purchase | A | 2,000 | 13.11 | 26,220.00 |
| 2022-12-02 | Patel Snehal | officer: CEO and CFO | 2,722,886 | P-Purchase | A | 1,000 | 13.84 | 13,840.00 |
| 2022-12-02 | Thompson Jaye | officer: VP Clinical Reg Affairs | 256,245 | P-Purchase | A | 250 | 13.98 | 3,495.00 |
| 2022-11-02 | Patel Snehal | officer: CEO and CFO | 2,721,886 | P-Purchase | A | 2,000 | 8.79 | 17,580.00 |
| 2022-10-14 | Patel Snehal | officer: CEO and CFO | 2,719,886 | P-Purchase | A | 3,000 | 9.75 | 29,250.00 |
| 2022-10-07 | Patel Snehal | officer: CEO and CFO | 2,716,886 | P-Purchase | A | 2,000 | 9.72 | 19,440.00 |
| 2022-09-30 | Patel Snehal | officer: CEO and CFO | 2,714,886 | P-Purchase | A | 1,000 | 9.46 | 9,460.00 |
| 2022-09-29 | Patel Snehal | officer: CEO and CFO | 2,713,886 | P-Purchase | A | 1,000 | 9.23 | 9,230.00 |
| 2022-06-24 | Patel Snehal | officer: CEO and CFO | 2,706,421 | P-Purchase | A | 22,535 | 9.13 | 205,745.00 |
| 2022-06-22 | Daugherty Frank Joseph | officer: Chief Medical Officer | 104,890 | A-Award | A | 104,890 | 0.00 | 0.00 |
| 2022-06-22 | Daugherty Frank Joseph | director, officer: Chief Medical Officer | 104,890 | A-Award | A | 104,890 | 7.63 | 800,311.00 |
| 2022-06-22 | Patel Snehal | officer: CEO and CFO | 1,073,731 | A-Award | A | 25,008 | 0.00 | 0.00 |
| 2022-06-22 | Thompson Jaye | officer: VP Clinical Reg Affairs | 149,818 | A-Award | A | 149,818 | 0.00 | 0.00 |
| 2022-06-22 | Hallock Kenneth | director: | 41,349 | A-Award | A | 41,349 | 0.00 | 0.00 |
| 2022-06-22 | Hallock Kenneth | director | 41,349 | A-Award | A | 41,349 | 7.63 | 315,493.00 |
| 2022-06-22 | Rothe Eric | director: | 41,349 | A-Award | A | 41,349 | 0.00 | 0.00 |
| 2022-06-22 | McWilliams David | director: | 61,984 | A-Award | A | 61,984 | 0.00 | 0.00 |
| 2022-06-16 | Patel Snehal | officer: CEO and CFO | 2,683,886 | P-Purchase | A | 8,000 | 7.13 | 57,040.00 |
| 2022-06-14 | Patel Snehal | officer: CEO and CFO | 2,675,886 | P-Purchase | A | 12,000 | 7.91 | 94,920.00 |
| 2022-06-10 | Patel Snehal | officer: CEO and CFO | 2,663,886 | P-Purchase | A | 12,000 | 8.33 | 99,960.00 |
| 2022-06-09 | Patel Snehal | officer: CEO and CFO | 1,243,453 | P-Purchase | A | 4,500 | 10.90 | 49,050.00 |
| 2022-06-07 | Patel Snehal | officer: CEO and CFO | 1,238,953 | P-Purchase | A | 6,000 | 8.55 | 51,300.00 |
| 2022-06-03 | Patel Snehal | officer: CEO and CFO | 1,232,953 | P-Purchase | A | 9,250 | 8.35 | 77,238.00 |
| 2022-06-02 | Patel Snehal | officer: CEO and CFO | 1,223,703 | P-Purchase | A | 6,774 | 7.38 | 49,992.00 |
| 2022-04-25 | Daugherty Frank Joseph | officer: Chief Medical Officer | 90,121 | P-Purchase | A | 1,000 | 16.25 | 16,250.00 |
| 2022-04-21 | Patel Snehal | officer: CEO and CFO | 1,216,929 | P-Purchase | A | 6,000 | 16.09 | 96,540.00 |
| 2022-04-19 | Patel Snehal | officer: CEO and CFO | 1,210,929 | P-Purchase | A | 6,000 | 16.74 | 100,440.00 |
| 2022-04-19 | Thompson Jaye | officer: VP Clinical Reg Affairs | 255,995 | P-Purchase | A | 500 | 16.74 | 8,370.00 |
| 2022-02-11 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 1,204,929 | P-Purchase | A | 5,500 | 19.80 | 108,900.00 |
| 2022-02-04 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 1,199,429 | P-Purchase | A | 5,000 | 19.59 | 97,950.00 |
| 2022-01-31 | Thompson Jaye | officer: VP Clinical Reg Affairs | 255,495 | P-Purchase | A | 500 | 18.47 | 9,235.00 |
| 2022-01-21 | Thompson Jaye | officer: VP Clinical Reg Affairs | 254,995 | P-Purchase | A | 500 | 16.33 | 8,165.00 |
| 2022-01-21 | Hallock Kenneth | director | 397,304 | P-Purchase | A | 300 | 16.32 | 4,896.00 |
| 2022-01-18 | Thompson Jaye | officer: VP Clinical Reg. Affairs | 254,495 | P-Purchase | A | 500 | 18.87 | 9,435.00 |
| 2022-01-13 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 1,194,429 | P-Purchase | A | 1,000 | 19.99 | 19,990.00 |
| 2022-01-13 | Thompson Jaye | officer: VP Clinical Reg. Affairs | 253,995 | P-Purchase | A | 1,000 | 19.99 | 19,990.00 |
| 2022-01-13 | Daugherty Frank Joseph | director, officer: Chief Medical Officer | 89,121 | P-Purchase | A | 1,000 | 19.99 | 19,990.00 |
| 2021-12-20 | Thompson Jaye | officer: VP Clinical & Reg. Affairs | 252,995 | D | 0 | 0.00 | 0.00 | |
| 2022-01-03 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 1,193,429 | P-Purchase | A | 2,050 | 23.82 | 48,831.00 |
| 2021-12-14 | Patel Snehal | director, 10 percent owner, officer: CEO and CFO | 1,191,379 | P-Purchase | A | 1,840 | 27.17 | 49,992.00 |
| 2021-12-14 | Daugherty Frank Joseph | director, officer: Chief Medical Officer | 88,121 | P-Purchase | A | 1,111 | 26.99 | 29,983.00 |
| 2021-12-14 | McWilliams David | director | 620,301 | P-Purchase | A | 200 | 27.56 | 5,512.00 |
| 2021-04-13 | Patel Snehal | director, officer: CEO and CFO | 1,189,539 | P-Purchase | A | 2,700 | 36.98 | 99,853.00 |
| 2020-11-10 | Patel Pankaj Amrit | 10 percent owner | 0 | J-Other | D | 187,266 | 0.00 | 0.00 |
| 2020-11-24 | Hallock Kenneth | director | 397,004 | P-Purchase | A | 1,000 | 5.39 | 5,386.00 |
| 2020-11-23 | Daugherty Frank Joseph | director, officer: Chief Medical Officer | 87,010 | P-Purchase | A | 1,000 | 5.10 | 5,100.00 |
| 2020-11-20 | McWilliams David | director | 620,101 | P-Purchase | A | 1,500 | 5.40 | 8,100.00 |
| 2020-11-20 | Hallock Kenneth | director | 396,004 | P-Purchase | A | 1,000 | 5.37 | 5,370.00 |
| 2020-11-20 | Rothe Eric | director | 313,226 | P-Purchase | A | 2,000 | 5.40 | 10,800.00 |
| 2020-11-19 | Patel Snehal | director, officer: CEO and CFO | 1,186,839 | P-Purchase | A | 2,000 | 5.40 | 10,795.00 |
| 2020-09-29 | Patel Kinnary | 10 percent owner | 129,400 | M-Exempt | A | 52,620 | 0.00 | 0.00 |
| 2020-09-29 | Patel Kinnary | 10 percent owner | 76,780 | M-Exempt | A | 76,780 | 0.00 | 0.00 |
| 2020-09-29 | Patel Kinnary | 10 percent owner | 7,292 | J-Other | A | 7,292 | 0.00 | 0.00 |
| 2020-09-29 | Patel Kinnary | 10 percent owner | 0 | M-Exempt | D | 76,780 | 0.00 | 0.00 |
| 2020-09-29 | Patel Kinnary | 10 percent owner | 0 | M-Exempt | D | 7,292 | 0.00 | 0.00 |
| 2020-09-24 | Patel Kinnary | 10 percent owner | 2,405,670 | I | 0 | 0.00 | 0.00 | |
| 2020-09-24 | Patel Kinnary | 10 percent owner | 1,329,590 | I | 0 | 0.00 | 0.00 | |
| 2020-09-24 | Patel Kinnary | 10 percent owner | 1,320,226 | I | 0 | 0.00 | 0.00 | |
| 2020-09-24 | Patel Kinnary | 10 percent owner | 0 | I | 76,780 | 0.00 | 0.00 |
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
